Xdemvy
(Lotilaner)Phase 2Small molecule
Xdemvy is one of 16 small molecule programs targeting Rosacea. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
15
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
9
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
17 competitors in Rosacea
#DrugCompanyPhaseTrials
1Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Alphagan
NovartisApproved
Minocin
TTriax
Approved
Flagyl
DDePuy Orthopaedics
Approved
Avlosulfon
AAlmirall, S.A.
Approved
Retin-a
VValeant Pharmaceuticals
Approved
Stromectol
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Elavil
AstraZenecaPhase 2
Tofranil
SanofiPhase 2
Seysara
AAlmirall, S.A.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Jul 24, 2023
XDEMVY
NDA NDA217603
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lotilaner. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Xdemvy. U.S. Food & Drug Administration.
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTarsus Pharmaceuticals, Inc.